Publicaciones en colaboración con investigadores/as de Clínica Universitaria de Navarra (23)

2020

  1. Challenges and opportunities of cfDNA analysis implementation in clinical practice: Perspective of the International Society of Liquid Biopsy (ISLB)

    Critical Reviews in Oncology/Hematology, Vol. 151

2019

  1. Improvement of appropriate pharmacological prophylaxis in hospitalised cancer patients with a multiscreen e-alert system: a single-centre experience

    Clinical and Translational Oncology, Vol. 21, Núm. 6, pp. 805-809

2018

  1. Insights into venous thromboembolism prevention in hospitalized cancer patients: Lessons from a prospective study

    PLoS ONE, Vol. 13, Núm. 8

2017

  1. Plasma rich in growth factors for the treatment of rapidly progressing refractory corneal melting due to erlotinib in nonsmall cell lung cancer

    Medicine (United States), Vol. 96, Núm. 22

2016

  1. AZD9291 in TKI EGFR resistance in non-small cell lung cancer and the new concept of phase I trials

    Translational Lung Cancer Research

  2. Dose escalation with external beam radiation therapy and high-dose-rate brachytherapy combined with long-term androgen deprivation therapy in high and very high risk prostate cancer: Comparison of two consecutive high-dose-rate schemes

    Brachytherapy, Vol. 15, Núm. 2, pp. 127-135

  3. Stereotactic body radiation therapy (SBRT) delays the emergence of castration resistance in patients with oligometastatic prostate cancer

    Clinical and Translational Oncology, Vol. 18, Núm. 7, pp. 743-747

2015

  1. Factors influencing the use of thromboprophylaxis in cancer outpatients in clinical practice: A prospective study

    Thrombosis Research, Vol. 136, Núm. 6, pp. 1145-1148

  2. Myopathy in hereditary leiomyomatosis and renal cell cancer in an extended family

    British Journal of Dermatology

  3. Pneumomediastinum as a complication of SABR for lung metastases

    Radiation Oncology, Vol. 10, Núm. 1

2013

  1. High incidence of venous thromboembolism despite electronic alerts for thromboprophylaxis in hospitalised cancer patients

    Thrombosis and Haemostasis, Vol. 110, Núm. 1, pp. 184-190

2012

  1. External-beam radiation therapy and high-dose rate brachytherapy combined with long-term androgen deprivation therapy in high and very high prostate cancer: Preliminary data on clinical outcome

    International Journal of Radiation Oncology Biology Physics, Vol. 82, Núm. 3

  2. Pathological vertebral fracture after stereotactic body radiation therapy for lung metastases. Case report and literature review

    Radiation Oncology, Vol. 7, Núm. 1

2011

  1. Nonconvulsive status epilepticus related to posterior reversible leukoencephalopathy syndrome induced by cetuximab

    Neurologist, Vol. 17, Núm. 5, pp. 273-275

2009

  1. Factores ligados a angiogénesis, coagulación y fibrinólisis en el pronóstico de pacientes con cáncer colorectal

    Salud(i)Ciencia, Vol. 16, Núm. 8, pp. 848-854

  2. Fibrosing cholestatic hepatitis following cytotoxic chemotherapy for small-cell lung cancer

    World Journal of Gastroenterology, Vol. 15, Núm. 18, pp. 2290-2292

  3. Identification of TNF-α and MMP-9 as potential baseline predictive serum markers of sunitinib activity in patients with renal cell carcinoma using a human cytokine array

    British Journal of Cancer, Vol. 101, Núm. 11, pp. 1876-1883

  4. Unresectableliver metastases from colorectal cancer and hepatic arterial infusion chemotherapy: How, when and to whom?

    CardioVascular and Interventional Radiology

2008

  1. Identification of VEGF-regulated genes associated with increased lung metastatic potential: Functional involvement of tenascin-C in tumor growth and lung metastasis

    Oncogene, Vol. 27, Núm. 40, pp. 5373-5384

2006

  1. New prognostic and predictive factors in advanced colorectal cancer

    Medicina Clinica, Vol. 126, Núm. 14, pp. 541-548